India has been pretty open and vocal about ignoring pharma patents when it comes to medications. They put the needs of the people above the financial wants of the industry.
It's been a cause of tension in trade negotiations.
>India’s law sets a higher bar for protection than in some other countries, limiting the ability of companies to get patents for new versions of drugs whose active ingredients were previously known unless they can show significant therapeutic benefit.
It's not ignoring patents, it's setting a high bar for them. You can't rehash old medicine and patent them.
It's been a cause of tension in trade negotiations.